Another Vaccine Now in the Final Stages of Testing

0
1130

Months into the pandemic, more companies are entering the final stages of vaccine testing.

Just over the last few days, Novavax (NVAX) said it would start its Phase 3 trial among 30,000 people in the UK.  In additional, a trial of 30,000 could begin in the U.S. if regulators are pleased with the safest of a Phase 2 trial under way at the moment, according to Barron’s.

The latest study in the UK will track whether adults receiving a two-dose vaccine see a lower rate of symptomatic COVID, as compared to those receiving the placebo.

Other than Novavax, Johnson & Johnson has Phase 3 trials under way, too.

The company expects results of its Phase 3 trials by the close of this year, or early 2021.  If successful, it could manufacture up to a billion doses in the new year.  In addition, unlike its competition, Johnson & Johnson’s vaccine may only require one dose of the vaccine.

“The benefits of a single-shot vaccine are potentially profound in terms of mass immunization campaigns and global pandemic control,” Dr. Dan Barouch, a Harvard vaccine researcher who helped design J&J’s COVID-19 vaccine, as quoted by Reuters.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here